Open AccessReal-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors
Author(s) -
Daneng Li,
Christina Darden,
Noran Osman,
Salma Sayeed,
Laurin Jackson,
Diana Garbinsky,
Aman Chauhan
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s386419
Subject(s) - medicine , neuroendocrine tumors , oncology
Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor approved for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analogs (SSAs).